Pharmacokinetic Properties of Lorcaserin in Subjects With Renal Impairment
2019年9月11日 更新者:Eisai Inc.
A Phase 1, Open-Label, Single-Dose Study of the Pharmacokinetic Properties of Lorcaserin in Subjects With Renal Impairment
The purpose of this study is to evaluate the PK properties of lorcaserin in subjects with end stage renal disease (ESRD) who require dialysis and will be studied under dialysis and non-dialysis conditions.
研究概览
研究类型
介入性
注册 (预期的)
40
阶段
- 阶段1
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习地点
-
-
Florida
-
Orlando、Florida、美国、32809
- Orlando Clinical Research Center
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
18年 至 79年 (成人、年长者)
接受健康志愿者
是的
有资格学习的性别
全部
描述
Inclusion Criteria:
- Males or females aged between 18 and 79 years (inclusive)
- Able to give signed informed consent
Renal function will fall into one of the following categories (ideal body weight will be used for the calculation):
- One-fifth of subjects will have normal renal function, defined as creatinine clearance > 80 mL/min calculated using the Cockroft-Gault equation
- One-fifth of subjects will have creatinine clearance 51-80 mL/min
- One-fifth of subjects will have creatinine clearance 31-50 mL/min
- One-fifth of subjects will have creatinine clearance 5-30 mL/min, but not require dialysis
- One-fifth of subjects will have chronic end stage renal disease, require regularly scheduled hemodialysis, and be on a stable hemodialysis regimen for at least 3 months prior to dosing
- Subjects in the renally impaired groups will have stable renal disease as per Investigator's assessment, with no clinically meaningful changes for 1 month prior to randomization.
- Subjects in all groups will have a BMI of 27-45 kg/m2.
- Considered to be in stable health in the opinion of the Investigator.
- Eligible male and female subjects must agree not to participate in a conception process.
Exclusion Criteria:
- Prior participation in any study of lorcaserin.
- Clinically significant new illness in the 1 month before screening
- Not suitable to participate in the study in the opinion of the Investigator including an existing physical or mental condition that prevents compliance with the protocol
History of any of the following cardiovascular conditions:
- Myocardial infarction (diagnosed by cardiac enzyme[s] and/or diagnostic ECG), CVA, TIA or RIND within 3 months of screening
- Cardiac arrhythmia requiring initiation of a new medical or surgical treatment within 3 months of screening (pacemaker and/or defibrillator implanted > 3 months prior to screening is acceptable)
- Unstable angina
- History of pulmonary artery hypertension
- Positive result of HIV, hepatitis B or hepatitis C screens.
- Malignancy within 2 years of the screening visit (except basal cell or squamous cell carcinoma with clean surgical margins)
- Use of SSRI's, SNRI's, and other medications must meet washout period.
- Recent history (within 3 months prior to the screening visit) of alcohol or drug/solvent abuse or a positive screen for drugs of abuse at screening.
- Participated in any clinical study with an investigational drug, biologic, or device within 1 month prior to dosing
- Unwilling, or whose partner is unwilling, to use an adequate means of contraception during and for 1 month following completion/withdrawal of the study
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:其他
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
实验性的:氯卡色林 10mg
|
研究衡量的是什么?
主要结果指标
结果测量 |
---|
The primary objective of this study is to assess the pharmacokinetic properties of lorcaserin in subjects with mild, moderate or severe renal impairment as compared to subjects with normal renal function.
|
次要结果测量
结果测量 |
---|
To evaluate the safety and tolerability of lorcaserin in subjects with renal impairment.
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
赞助
出版物和有用的链接
负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始
2008年10月1日
初级完成 (实际的)
2009年2月1日
研究完成 (实际的)
2009年2月1日
研究注册日期
首次提交
2009年1月22日
首先提交符合 QC 标准的
2009年1月23日
首次发布 (估计)
2009年1月26日
研究记录更新
最后更新发布 (实际的)
2019年9月12日
上次提交的符合 QC 标准的更新
2019年9月11日
最后验证
2009年7月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
Lorcaserin 10mg的临床试验
-
Eisai Inc.完全的
-
424 General Military HospitalAristotle University Of Thessaloniki招聘中
-
AstraZeneca完全的佐林格-埃里森综合症 | 反流性食管炎 (RE) | 胃溃疡 (GU) | 十二指肠溃疡 (DU) | 吻合口溃疡(澳大利亚) | 非糜烂性反流性食管炎 (NERD)日本